PHASE II TRIAL OF HIGH-DOSE GEMCITABINE/BUSULFAN/MELPHALAN WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR PRIMARY REFRACTORY OR POOR-RISK RELAPSED HODGKIN’S LYMPHOMA

We conducted a prospective phase 2 trial of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) with autologous stem-cell transplantation (ASCT) in Hodgkin’s lymphoma (HL) patients with primary refractory or poor-risk relapsed disease (extranodal relapse or within 1 year of frontline therapy). The tria...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biol Blood Marrow Transplant
Main Authors: Nieto, Yago, Thall, Peter F, Ma, Junsheng, Valdez, Benigno C, Ahmed, Sairah, Anderlini, Paolo, Popat, Uday, Jones, Roy B, Shpall, Elizabeth J, Hosing, Chitra, Qazilbash, Muzaffar, Kebriaei, Partow, Alousi, Amin, Timmons, Melissa, Gulbis, Alison, Myers, Alan, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Milgrom, Sarah, Champlin, Richard, Andersson, Borje S
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8212703/
https://ncbi.nlm.nih.gov/pubmed/29501779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2018.02.020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados